02.17.17
Alexion
4Q Revenues: $831 million (+19)
4Q Earnings: $93 million (+39%)
FY Revenues: $3.1 billion (+18%)
FY Earnings: $399 million (+177%)
Comments: Soliris sales were $2.8 billion for the year, up 10%. Strensiq sales were $210 million, compared to $12 million in 2015. Kanuma sales were $29 million. R&D expenses were $757 million for the year, up 7%.
4Q Revenues: $831 million (+19)
4Q Earnings: $93 million (+39%)
FY Revenues: $3.1 billion (+18%)
FY Earnings: $399 million (+177%)
Comments: Soliris sales were $2.8 billion for the year, up 10%. Strensiq sales were $210 million, compared to $12 million in 2015. Kanuma sales were $29 million. R&D expenses were $757 million for the year, up 7%.